| [1] |
Alexandru-Abrams D, Jadus MR, Hsu FP, et al. Therapeutic targeting of malignant glioma[J]. Anticancer Agents Med Chem, 20 14, 14(8): 1075-84.
|
| [2] |
Zhou ZL, Bu XY, Yan ZY, et al. Effects of rendezvous chemotherapy compined with three-dimensional comformal radiotherapy in treatment for post-operative malignant glioma[J]. Zhong Liu Fang Zhi Yan Jiu, 2014, 41(4): 374-8. [周志龙, 步星耀, 闫兆月, 等. 脑恶性胶质瘤术后会师化疗同步适形放疗的临床 观察[J] 肿瘤防治研究, 2014, 41(4): 374-8.]
|
| [3] |
Kitanaka C, Sato A, Okada M. JNK Signaling in the Control of the Tumor-Initiating Capacity Associated with Cancer Stem Cells[J]. Genes Cancer, 2013, 4(9-10): 388-96.
|
| [4] |
Li JY, Wang H, May S, et al. Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas[J]. J Neurooncol, 2008, 88(1): 11-7.
|
| [5] |
Dong L, Ge RM, Qi N, et al. JNK1 knockdown via adenovirusmediated shRNA inhibited cell proliferation in U87MG gliobalstoma cells[J]. Zhong Liu Fang Zhi Yan Jiu, 2011, 38(7): 76 7-9. [董林, 葛瑞民, 祁楠, 等. shRNA腺病毒介导的JNK1 RNAi抑制U87MG人胶质瘤细胞的增殖[J]. 肿瘤防治研究, 20 11, 38(7): 767-9.]
|
| [6] |
Cui J, Han SY, Wang C, et al. c-Jun NH(2)-terminal kinase 2alpha2 promotes the tumorigenicity of human glioblastoma cells[J]. Cancer Res, 2006, 66(20): 10024-31.
|
| [7] |
Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights[J]. Pharmacol Ther, 20 14, 143(3): 323-36.
|
| [8] |
Noureen N, Rashid H, Kalsoom S. Identification of type-specific anticancer histone deacetylase inhibitors: road to success[J]. Cancer Chemother Pharmacol, 2010, 66(4): 625-33.
|
| [9] |
Slingerland M, Guchelaar HJ, Gelderblom H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors[J]. Anticancer Drugs, 2014, 25(2): 140-9.
|
| [10] |
Yuan Z, Gong S, Luo J, et al. Opposing roles for ATF2 and c-Fos in c-Jun-mediated neuronal apoptosis[J]. Mol Cell Biol, 2009, 29 (9): 2431-42.
|
| [11] |
Guo Y, Wang W, Wang J, et al. Receptor for activated C kinase 1 promotes hepatocellular carcinoma growth by enhancing mitogenactivated protein kinase kinase 7 activity[J]. Hepatology, 2013, 57 (1): 140-51.
|
| [12] |
Kaikai S, Yuchen S, Lili J, et al. Critical role of c-Jun N-terminal kinase in regulating bFGF-induced angiogenesis in vitro[J]. J Biochem, 2011, 150(2): 189-97.
|
| [13] |
Rennefahrt U, Illert B, Greiner A, et al. Tumor induction by activated JNK occurs through deregulation of cellular growth[J]. Cancer Lett, 2004, 215(1): 113-24.
|
| [14] |
Miyazaki T, Bub JD, Iwamoto Y. c-Jun NH(2)-terminal kinase mediates leptin-stimulated androgen-independent prostate cancer cell proliferation via signal transducer and activator of transcription 3 and Akt[J]. Biochim Biophys Acta, 2008, 17 82(10): 593-604.
|
| [15] |
Nalabothula N, Carrier F. Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization[J]. Epigenomics, 2011, 3(2): 145-55.
|
| [16] |
Sarkar D, Leung EY, Baguley BC, et al. Epigenetic regulation in human melanoma: past and future[J]. Epigenetics, 2015, 10(2): 10 3-21.
|
| [17] |
Rosato R, Hock S, Dent P, et al. LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism[J]. Leuk Res, 2012, 36(4): 491-8.
|
| [18] |
Sharma V, Koul N, Joseph C, et al. HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity[J]. J Cell Mol Med, 2010, 14(8): 2151-61.
|
下载:
